A triple combination cancer immunotherapy based regimen containing adoptive T cell therapy, a PIM kinase inhibitor, and a PD-1 inhibitor could improve survival in a mouse model of melanoma
from Medindia Health News https://ift.tt/2QpNhck
LATEST HEALTH NEWS
Reviewed by MZ Digital Marketing Agency
on
November 30, 2018
Rating: 5
No comments
Thanks for comment via will connect you within 24 hours.
No comments
Thanks for comment via will connect you within 24 hours.